Funded Clinical Trial for Dogs with Hemangiosarcoma is now closed.

07/26/2010
Trial Summary

This clinical trial will evaluate a novel anti-cancer agent in a limited number of dogs with hemangiosarcoma. All dogs will receive study drug; there is no placebo.

Dogs will receive the study drug as daily, oral treatment with evaluations performed once weekly for the first 28 days, then once monthly. Blood samples are collected throughout the study to assess the metabolism and biological activity of this drug.

During the course of the study, dogs will not be allowed any holistic therapy, chemotherapy, prednisone therapy, non-steroidal anti-inflammatory therapy or other investigational therapies unless approved by the investigator and the sponsor.


Trial Support and Funding
Study drug, diagnostic tests, and follow-up exams will be paid for by the study sponsor. In the event that side effects are attributed to the study drug, the study will pay for medical management of the side effects.

Trial Eligibility
Client-owned pet dogs with measurable hemangiosarcoma lesions (primary or metastatic); OR patients free of gross disease, having undergone splenectomy within the past 28 days.
In addition, cases must meet the following criteria:
-Generally feeling well;
-Prior treatment with chemotherapy acceptable with a required washout of 21 days;
-Prior treatment with non-steroidal anti-inflammatory drugs (NSAID) and prednisone acceptable with a required 14-day washout;
-Prior treatment with radiation therapy is acceptable with a required 30-day washout;
-No prior small molecule inhibitors (i.e. Palladia™);
-No prior immunotherapy (i.e. ONCEPT™ melanoma vaccine).


For additional information please contact us at (781) 684-8688.